Q-omics provides the consensus-scored ZNF66 profile across patient tissues and cancer cell-line models. ZNF66 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF66 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF66 RNA expression shows 20,474 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZNF66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF66 survival associations across molecular data types. ZNF66 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF66 RNA expression–survival associations across cancer types. High ZNF66 expression shows unfavorable associations in LIHC, KICH and ACC, but favorable associations in KIRC, UCS and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF66 RNA expression.
This table summarizes ZNF66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF66 shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, BRCA, LIHC and COAD. The THCA box plot shows higher ZNF66 RNA expression in normal versus tumor tissue (log2 FC = −0.597, t-test p < 0.001).
This table shows molecular features associated with ZNF66 in patient tissues and cancer cell lines. In patient samples, ZNF66 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF66 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
